Trial · NCT01945021
Adverse events111
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
41 to 60 of 111
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dyspnoea | Respiratory, thoracic and mediastinal disorders | Crizotinib 250 mg | 12 | 127 | |
| other | Rash | Skin and subcutaneous tissue disorders | Crizotinib 250 mg | 17 | 127 | |
| other | Pruritis | Skin and subcutaneous tissue disorders | Crizotinib 250 mg | 11 | 127 | |
| other | Abdominal distension | Gastrointestinal disorders | Crizotinib 250 mg | 8 | 127 | |
| other | Toothache | Gastrointestinal disorders | Crizotinib 250 mg | 10 | 127 | |
| other | Asthenia | General disorders | Crizotinib 250 mg | 9 | 127 | |
| other | Pain | General disorders | Crizotinib 250 mg | 9 | 127 | |
| other | Peripheral swelling | General disorders | Crizotinib 250 mg | 9 | 127 | |
| other | Hepatic function abnormal | Hepatobiliary disorders | Crizotinib 250 mg | 10 | 127 | |
| other | Blood albumin decreased | Investigations | Crizotinib 250 mg | 17 | 127 | |
| other | Blood creatine phosphokinase increased | Investigations | Crizotinib 250 mg | 9 | 127 | |
| other | Protein total decreased | Investigations | Crizotinib 250 mg | 7 | 127 | |
| other | Weight decreased | Investigations | Crizotinib 250 mg | 8 | 127 | |
| other | Hypocalcaemia | Metabolism and nutrition disorders | Crizotinib 250 mg | 10 | 127 | |
| other | Hypokalaemia | Metabolism and nutrition disorders | Crizotinib 250 mg | 10 | 127 | |
| other | Hyponatraemia | Metabolism and nutrition disorders | Crizotinib 250 mg | 12 | 127 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Crizotinib 250 mg | 10 | 127 | |
| other | Musculoskeletal pain | Musculoskeletal and connective tissue disorders | Crizotinib 250 mg | 10 | 127 | |
| other | Hypoaesthesia | Nervous system disorders | Crizotinib 250 mg | 7 | 127 | |
| other | Taste disorder | Nervous system disorders | Crizotinib 250 mg | 8 | 127 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01945021/events?page=3